Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: Potential implications for pneumococcal conjugate vaccines

Abstract Acute otitis media (AOM) is the most common infection following pneumococcal colonization of the upper respiratory tract. Streptococcus pneumoniae causes 30–60% of AOM cases worldwide. However, not all pneumococcal serotypes cause disease and an association exists with nasopharyngeal coloni...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2009-06, Vol.27 (29), p.3802-3810
Main Authors: Rodgers, Gail L, Arguedas, Adriano, Cohen, Robert, Dagan, Ron
Format: Article
Language:English
Subjects:
Adolescent
Allergy and Immunology
Applied microbiology
Bacterial Typing Techniques
Bacteriology
Biological and medical sciences
Child
Child, Preschool
Fundamental and applied biological sciences. Psychology
Humans
Infant
Microbiology
Miscellaneous
Otitis media
Otitis Media - epidemiology
Otitis Media - microbiology
Pneumococcal Infections - epidemiology
Pneumococcal Infections - microbiology
Pneumococcal Vaccines - immunology
Serotype
Serotyping
Streptococcus pneumoniae
Streptococcus pneumoniae - classification
Streptococcus pneumoniae - isolation & purification
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Conjugate - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Acute otitis media (AOM) is the most common infection following pneumococcal colonization of the upper respiratory tract. Streptococcus pneumoniae causes 30–60% of AOM cases worldwide. However, not all pneumococcal serotypes cause disease and an association exists with nasopharyngeal colonization by certain serotypes and their propensity to cause AOM. This review examines the global serotype distribution relationship between pneumococcal serotypes and AOM in children aged
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2009.04.021